Top Markets
#1 Akedo Akedo +59.62%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.64%
#4 Cross Cross +40.87%
#5 OVERTAKE OVERTAKE +34.07%
#6 Black Phoenix Black Phoenix +33.88%
#7 Velvet Velvet +33.26%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.83%
#9 Cap Cap +15.68%
#10 Bitway Bitway +11.60%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Valion Bio, Inc. Valion Bio, Inc.

Valion Bio, Inc.

VBIO
Rank in Stocks #38930
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Share Price
$0.1818
Market Cap
$752.91K
Change (1 day)
6.44%
Change (1 year)
-94.81%
Country
US
Trade Valion Bio, Inc. (VBIO)

Category

Healthcare
Earnings for Valion Bio, Inc. (VBIO)
Earnings in 2026 TTM: 0
According to Valion Bio, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Valion Bio, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE